In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period

• Published in: Journal of chemotherapy (Florence) 2015-10, Vol.27 (5), p.266-270
• Main Authors: Spiliopoulou, Anastasia, Jelastopulu, Eleni, Vamvakopoulou, Sofia, Bartzavali, Christina, Kolonitsiou, Fevronia, Anastassiou, Evangelos D., Christofidou, Myrto
• Format: Article
• Language: English
• Subjects: A. baumanni; Acinetobacter baumannii - drug effects; Acinetobacter baumannii - isolation & purification; Acinetobacter Infections - drug therapy; Acinetobacter Infections - microbiology; Anti-Bacterial Agents - pharmacology; Bloodstream infections; Colistin; Colistin - pharmacology; Drug Resistance, Multiple, Bacterial - drug effects; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Minocycline - analogs & derivatives; Minocycline - pharmacology; Multidrug resistance; Tertiary Care Centers; Tigecycline; Time Factors
• ISSN: 1120-009X; 1973-9478
• DOI: 10.1179/1973947814Y.0000000193

Acinetobacter baumannii has emerged as an important and problematic pathogen causing bloodstream infections (BSI) in hospitalized patients. Results of an 8-year period from a university hospital are presented. Identification of A. baumannii was performed by Gram-negative BD BBL Crystal ID and VITEK®2 system, whereas, susceptibility testing by VITEK2, Kirby-Bauer disc system, and Etest strips. Interpretation of results was based on CLSI criteria and, regarding tigecycline, Food and Drug Administration (FDA) criteria. Between 2006 and 2013, 441 among 7088 BSI cases were attributed to A. baumannii. Of all isolates, 92·1% were resistant to more than three classes of antibiotics and 79·4% were resistant to all but one or two categories of antimicrobials. Resistance to ampicillin-sulbactam, meropenem, gentamicin, ciprofloxacin, minocycline, and tigecycline increased during the study period (P